Industry news

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Angus Liu / Fierce Pharma

Big Pharma’s businesses in emerging markets grew 6.1% sequentially in the second quarter, the fastest in more than two years, according to a recent tally by Bernstein analysts, but some grew much faster than others.

Iranian biotech drugs replaced American ones in Russia

Remedium

Iranian biotech medicines exported to Russia have taken over the country’s market 100% and have replaced their American versions, according to National Talents Foundation.

Pfizer and LabCentral announced opening of a new facility

GMP News

LabCentral and Pfizer announced plans to open LabCentral 610, a new LabCentral offering located at Pfizer’s Kendall Square Worldwide Research and Development campus, Cambridge, Massachusetts, U.S. The facility is slated to open in December and will house up to six early- to mid-stage companies.

Russian University creates a bank of biomolecules for new drugs

GMP News

The research activities of Genomic and Regenerative Medicine Center established at the School of Biomedicine in the Far Eastern Federal University (FEFU) will be based on unique natural resources of the Russian Far East. The scientists will study the biodiversity of the region, including marine organisms, create a bank of biomolecules for new drugs, and introduce innovative diagnostic and treatment methods into routine medical practice.

Transition to multicomponent preventive drugs is necessary

GMP News

During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.

SPIC’s will ensure more predictability for pharmaceutical companies in Russia

GMP News

A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

Cancer biobank Indivumed and CRO Helomics team up on precision medicine

Angus Liu / Fierce Pharma

Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical datIndivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. collected from patients around the world to help advance research in personalized cancer treatments.

In a world of change, big pharma remains a constant

Andrew McConaghie / Dip Dive

Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise. Here pharmaphorum’s Andrew McConaghie crunches the numbers.

20 September 2017

India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

Joseph Keenan / Fierce Pharma

Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

19 September 2017

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.